Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug3825 | SNO Wiki | 0.71 |
drug4699 | Vitamins Wiki | 0.71 |
drug2818 | Nitrogen gas Wiki | 0.50 |
Name (Synonyms) | Correlation | |
---|---|---|
D013119 | Spinal Cord Injuries NIH | 0.27 |
D001930 | Brain Injuries, NIH | 0.20 |
D014947 | Wounds and Injuries NIH | 0.12 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There are 2 clinical trials
In adults with COVID-19 without criteria for hospitalization or oxygen therapy but with risk factors for aggravation, early treatment may avoid hospitalization, indication for oxygen therapy or death. No treatment is currently validated for this indication.
Description: Proportion of participants with an occurrence of death
Measure: Efficacy phase: Death Time: From inclusion (day0) to day 14Description: Proportion of participants who had an indication for oxygen therapy
Measure: Efficacy phase: oxygen therapy Time: From inclusion (day0) to day 14Description: Proportion of participants who had an indication for hospitalization
Measure: Efficacy phase: hospitalization Time: From inclusion (day0) to day 14Description: Proportion of deaths, overall and by cause, in each group
Measure: Death and causes of death Time: From inclusion (day0) to day 28Description: Evolution of Haematological markers in each group : Complete Blood Count, prothrombin level, INR
Measure: Haematological markers evolution Time: from inclusion (day 0) to day 7Description: Evolution of Inflammatory markers in each group : PCT, CRP
Measure: Inflammatory markers evolution Time: from inclusion (day 0) to day 7Description: Number and proportion of grade 1,2,3,4 adverse events in each group
Measure: Adverse events Time: from inclusion (day 0) to day 28Description: Number and proportion of grade 1,2,3,4 adverse events in each group
Measure: Adverse reactions Time: from inclusion (day 0) to day 28Description: Acceptability of the treatment by participant will be assessed with an interview
Measure: Acceptability of the treatment Time: from inclusion (day 0) to day 10Description: Proportion of participants who received at least one day of antibiotic therapy
Measure: Antibiotic consumption Time: from inclusion (day 0) to day 28Description: Proportion of participants who experienced a worsening of oxygen saturation
Measure: Oxygen saturation worsening Time: from inclusion (day 0) to day 28Description: Proportion of participants who completed the prescribed protocol treatment
Measure: protocol follow-up Time: from inclusion (day 0) to day 10The purpose of this study is to assess the safety and efficacy of Alvesco (ciclesonide) Inhalation Aerosol in non hospitalized patients with symptomatic COVID-19 infection in a multicenter, randomized, double-blind, placebo controlled study
Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports